Good afternoon, readers.
We're hunkered down and closing the upcoming issue of Fortune today. But in the meantime, I hope you'll follow along with my colleagues' outstanding coverage of the equally-outstanding Fortune Brainstorm Tech conference currently taking place in Aspen. And a note below on Genentech's "hat trick" of deals.
Read on for the day's news, back with much more tomorrow.
Intermountain Healthcare is launching a broad health care platform (with a digital assist). Utah-based Intermountain Healthcare is known for its experimental aspirations, whether as a leader in a nonprofit drug collaborative led by hospitals or its latest effort, a new health platform company called Castell. This new firm will reportedly attempt to create an easier primary care experience with a boost from digital technologies. “Castell is a critical component of Intermountain’s broad vision for healthier communities. It creates a new path for providers to access the support they need to provide high quality, affordable care to their patients across the nation,” said Intermountain CEO Marc Harrison in a statement.
Genentech goes on a deal spree. Call it a hat trick—biotech giant Genentech announced three separate deals in a single day. On Tuesday, the company struck collaborations with Sosei Heptares, Skyhawk Therapeutics, and Convelo Therapeutics, deals aimed at creating treatments for everything from cancer to brain disorders. (FierceBiotech)
THE BIG PICTURE
Ebola outbreak reaches crowded Congo city. The Ebola outbreak in the Congo reached a concerning new milestone this week as the Congolese government reported a case in Goma, a heavily populated city along the Rwandan border. While the patient was quickly transported to a treatment center, he had taken a bus from the more remote Butembo to the city, prompting authorities to track down his fellow passengers. (CBS News)
The 60 Best Companies to Work for in New York, by Fortune Editors
Goldman Sachs CEO David Solomon Says the Company Is Doubling Down on Diversity and Inclusion, by Christopher Tkaczyk
Commentary: Only Regulation Can Jump-Start Competition in Big Tech, by Gene Kimmelman & Charlotte Slaiman
Find past coverage. Sign up for other Fortune newsletters.